



Cancellation Summary

**Entity name**

PACIFIC EDGE LIMITED

**Announcement Type**

Cancellation of previous announcement

**Date of this announcement**

17/7/2025

**Reason for cancellation of previous announcement**

Replacement 3Bs issued 17 July 2025 update number and timing proposed shares relating to the Placement and the Retail offer.

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

**1.1 Name of +Entity**

PACIFIC EDGE LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

**1.2 Registered Number Type**

ARBN

**Registration Number**

653308144

**1.3 ASX issuer code**

PEB

**1.4 The announcement is**

Cancellation of previous announcement

**1.4c Reason for cancellation of previous announcement**

Replacement 3Bs issued 17 July 2025 update number and timing proposed shares relating to the Placement and the Retail offer.

**1.4d Date of previous announcement to this cancellation**

29/5/2025

**1.5 Date of this announcement**

17/7/2025

**1.6 The Proposed issue is:**

An offer of +securities under a +securities purchase plan

A placement or other type of issue

Part 4 - Details of proposed offer under securities purchase plan

---

Part 4A - Conditions

---

**4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis?**

Yes

## 4A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	11/7/2025	Estimated	

**Comments**

Completion of the share purchase plan will be conditional on the placement becoming unconditional. The placement is conditional on PEB obtaining all necessary or desirable shareholder approvals, and all necessary regulatory approvals, to complete the placement.



Part 4B - Offer details

**+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued**

**ASX +security code and description**

PEB : ORDINARY FULLY PAID FOREIGN EXEMPT NZX

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

Details of +securities proposed to be issued

**ASX +security code and description**

PEB : ORDINARY FULLY PAID FOREIGN EXEMPT NZX

**Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted**

50,000,000

**Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?**

No

**Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?**

No

**Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?**

No

**Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?**

Yes

**Is the maximum acceptance unit based or dollar based?**

Dollar based (\$)

**Please enter the maximum acceptance value**

\$ 50,000

**Describe all the applicable parcels available for this offer in number of securities or dollar value**

Right to subscribe for up to NZ \$50,000 in new shares. Applicable parcels to be determined.

**Offer price details**

**Has the offer price been determined?**

No



**In what currency will the offer be made?**

NZD - New Zealand Dollar

**How and when will the offer price be determined?**

Same price as Placement

**Oversubscription & Scale back details**

**Will a scale back be applied if the offer is over-subscribed?**

Yes

**Describe the scale back arrangements**

To be confirmed.

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

#### Part 4C - Timetable

**4C.1 Date of announcement of +security purchase plan**

30/5/2025

**4C.2 +Record date**

28/5/2025

**4C.3 Date on which offer documents will be made available to investors**

11/7/2025

**4C.4 Offer open date**

11/7/2025

**4C.5 Offer closing date**

25/7/2025

**4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer**

1/8/2025

#### Part 4E - Fees and expenses

**4E.1 Will there be a lead manager or broker to the proposed offer?**

No

**4E.2 Is the proposed offer to be underwritten?**

No

**4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?**



No

**4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer**

Standard legal, registry costs and corporate advisory fees to Cameron Partners in line with customary levels for transactions of this nature.

**Part 4F - Further Information**

**4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue**

Raise capital to ensure the company has the resources and capacity to capitalise on its recent clinical and commercial milestones, grow into non-Medicare channels and regain Medicare coverage

**4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?**

No

**4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer**

All jurisdictions except New Zealand

**4F.3 URL on the entity's website where investors can download information about the proposed offer**

<https://www.pacifiedgedx.com/>

**4F.4 Any other information the entity wishes to provide about the proposed offer**

Pacific Edge reserves the right to extend the share purchase plan to shareholders / beneficial owners with a registered address in Australia, subject to obtaining any necessary relief. If Pacific Edge decides to do so, it will provide details when it releases a further Corporate Action Notice to the NZX and an updated Appendix 3B.

The Record Date for the share purchase plan is yet to be determined. It is currently anticipated that it will be in July/August. PEB will release a further Corporate Action Notice and updated Appendix 3B when this is determined.

The Ex Date for the share purchase plan is yet to be determined. It is currently anticipated that it will be in July/August. PEB will release a further Corporate Action Notice and updated Appendix 3B when this is determined.

The Closing Date for the share purchase plan is yet to be determined. It is currently anticipated that it will be in July/August. PEB will release a further Corporate Action Notice and updated Appendix 3B when this is determined.

The Record Date for the share purchase plan is yet to be determined. It is currently anticipated that it will be in July/August. PEB will release a further Corporate Action Notice and updated Appendix 3B when this is determined.



## Part 7 - Details of proposed placement or other issue

## Part 7A - Conditions

**7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?**

Yes

## 7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	11/7/2025	Estimated	

**Comments**

Yes. The placement is conditional on PEB obtaining all necessary or desirable shareholder approvals, and all necessary regulatory approvals, to complete the placement.

## Part 7B - Issue details

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

Existing class

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

## Details of +securities proposed to be issued

**ASX +security code and description**

PEB : ORDINARY FULLY PAID FOREIGN EXEMPT NZX

**Number of +securities proposed to be issued**

150,000,000

**Offer price details**

**Are the +securities proposed to be issued being issued for a cash consideration?**

Yes

**In what currency is the cash consideration being paid?**

NZD - New Zealand Dollar

**What is the issue price per +security?**

NZD 0.10000

**AUD equivalent to issue price amount per +security**

0.093000



**FX rate (in format AUD 1.00 / primary currency rate):**

AUD 1.00

**FX rate (in format AUD rate/primary currency rate) Primary Currency rate**

NZD 1.08000000

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

## Part 7C - Timetable

### 7C.1 Proposed +issue date

11/7/2025

## Part 7D - Listing Rule requirements

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

No

## Part 7E - Fees and expenses

**7E.1 Will there be a lead manager or broker to the proposed issue?**

No

**7E.2 Is the proposed issue to be underwritten?**

No

**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

Standard legal, registry costs and corporate advisory fees to Cameron Partners in line with customary levels for transactions of this nature.

## Part 7F - Further Information

**7F.01 The purpose(s) for which the entity is issuing the securities**

Raise capital to ensure the company has the resources and capacity to capitalise on its recent clinical and commercial milestones, grow into non-Medicare channels and regain Medicare coverage.

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

No

**7F.2 Any other information the entity wishes to provide about the proposed issue**

**7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with**





**the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**  
An applicable ASIC instrument or class order

For personal use only